Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab

Area of Science:

• Immunology
• Infectious Diseases
• Pharmacology

Background:

• Eculizumab is a C5 complement inhibitor used to treat certain autoimmune and hematologic conditions.
• Patients treated with eculizumab have a documented increased risk of invasive meningococcal disease.
• Most meningococcal disease cases in eculizumab recipients are caused by encapsulated strains (e.g., serogroups A, B, C, W, Y).

Observation:

• This report details a rare case of fatal meningococcal disease in an eculizumab recipient.
• The causative agent was identified as a nongroupable Neisseria meningitidis strain.
• Nongroupable meningococcal strains are infrequently associated with severe disease in immunocompetent individuals.

Findings:

• The patient had received meningococcal vaccination prior to the infection.
• Despite vaccination and eculizumab therapy, the patient developed severe, fatal meningococcal disease.
• This case underscores the potential for unusual meningococcal strains to cause severe illness in complement-deficient patients.

Implications:

• Current meningococcal vaccination strategies may not fully protect eculizumab-treated patients against all meningococcal strains.
• There is a need to investigate the efficacy of existing vaccines against nongroupable meningococcal strains.
• Consideration of prophylactic or alternative treatment strategies may be warranted for eculizumab recipients, particularly those exposed to non-vaccine strains.